Sab Biotherapeutics Stock Buy Hold or Sell Recommendation
| SABS Stock | USD 4.29 0.17 3.81% |
Given the investment horizon of 90 days and your conservative attitude towards risk, our recommendation regarding SAB Biotherapeutics is 'Strong Sell'. Macroaxis provides SAB Biotherapeutics buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding SABS positions. The advice algorithm takes into account all of SAB Biotherapeutics' available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting SAB Biotherapeutics' buy or sell advice are summarized below:
Real Value 3.19 | Target Price 2.3 | Hype Value 4.62 | Market Value 4.29 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell SAB Biotherapeutics given historical horizon and risk tolerance towards SAB Biotherapeutics. When Macroaxis issues a 'buy' or 'sell' recommendation for SAB Biotherapeutics, the advice is generated through an automated system that utilizes algorithms and statistical models.
SAB |
Execute SAB Biotherapeutics Buy or Sell Advice
The SAB recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on SAB Biotherapeutics. Macroaxis does not own or have any residual interests in SAB Biotherapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute SAB Biotherapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Very risky | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Above Average | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
SAB Biotherapeutics Trading Alerts and Improvement Suggestions
| SAB Biotherapeutics generated a negative expected return over the last 90 days | |
| SAB Biotherapeutics has high historical volatility and very poor performance | |
| SAB Biotherapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 2.24 M. Net Loss for the year was (42.19 M) with loss before overhead, payroll, taxes, and interest of (12.53 M). | |
| SAB Biotherapeutics currently holds about 16.62 M in cash with (25.12 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.39. | |
| SAB Biotherapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 19.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: Chardan Capital Reaffirms Buy Rating for SAB Biotherapeutics - Defense World |
SAB Biotherapeutics current analysts advice
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. SAB analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. SAB analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Average Consensus Strong Buy
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.
SAB Biotherapeutics Returns Distribution Density
The distribution of SAB Biotherapeutics' historical returns is an attempt to chart the uncertainty of SAB Biotherapeutics' future price movements. The chart of the probability distribution of SAB Biotherapeutics daily returns describes the distribution of returns around its average expected value. We use SAB Biotherapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of SAB Biotherapeutics returns is essential to provide solid investment advice for SAB Biotherapeutics.
| Mean Return | -0.28 | Value At Risk | -8 | Potential Upside | 6.74 | Standard Deviation | 4.83 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of SAB Biotherapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
SAB Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as SAB Biotherapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading SAB Biotherapeutics backward and forwards among themselves. SAB Biotherapeutics' institutional investor refers to the entity that pools money to purchase SAB Biotherapeutics' securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Kestra Advisory Services, Llc | 2023-12-31 | 88 K | State Street Corporation | 2023-12-31 | 81.2 K | Mariner Wealth Advisors, Llc | 2023-12-31 | 69 K | Renaissance Technologies Corp | 2023-12-31 | 63.1 K | Blackrock Inc | 2023-12-31 | 52.6 K | Peapack Gladstone Financial Corp | 2023-12-31 | 52.3 K | Silver Oak Securities, Inc. | 2023-12-31 | 51.9 K | Creative Planning Inc | 2023-12-31 | 47.5 K | Advisor Group Holdings, Inc. | 2023-12-31 | 46.4 K | Rtw Investments, Llc | 2023-12-31 | 9.2 M | Marshall Wace Asset Management Ltd | 2023-12-31 | 4.6 M |
SAB Biotherapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to SAB Biotherapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that SAB Biotherapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a SAB stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | -0.31 | |
β | Beta against NYSE Composite | 0.41 | |
σ | Overall volatility | 4.96 | |
Ir | Information ratio | -0.07 |
SAB Biotherapeutics Volatility Alert
SAB Biotherapeutics exhibits very low volatility with skewness of -0.27 and kurtosis of 2.41. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure SAB Biotherapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact SAB Biotherapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.SAB Biotherapeutics Fundamentals Vs Peers
Comparing SAB Biotherapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze SAB Biotherapeutics' direct or indirect competition across all of the common fundamentals between SAB Biotherapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as SAB Biotherapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of SAB Biotherapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing SAB Biotherapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare SAB Biotherapeutics to competition |
| Fundamentals | SAB Biotherapeutics | Peer Average |
| Return On Equity | -0.96 | -0.31 |
| Return On Asset | -0.35 | -0.14 |
| Operating Margin | (61.88) % | (5.51) % |
| Current Valuation | (9.51 M) | 16.62 B |
| Shares Outstanding | 9.23 M | 571.82 M |
| Shares Owned By Insiders | 19.13 % | 10.09 % |
| Shares Owned By Institutions | 37.99 % | 39.21 % |
| Number Of Shares Shorted | 28.86 K | 4.71 M |
| Price To Book | 0.75 X | 9.51 X |
| Price To Sales | 19.26 X | 11.42 X |
| Revenue | 2.24 M | 9.43 B |
| Gross Profit | (12.53 M) | 27.38 B |
| EBITDA | (34.33 M) | 3.9 B |
| Net Income | (42.19 M) | 570.98 M |
| Cash And Equivalents | 16.62 M | 2.7 B |
| Cash Per Share | 0.39 X | 5.01 X |
| Total Debt | 5.91 M | 5.32 B |
| Debt To Equity | 0.16 % | 48.70 % |
| Current Ratio | 1.72 X | 2.16 X |
| Book Value Per Share | 6.21 X | 1.93 K |
| Cash Flow From Operations | (25.12 M) | 971.22 M |
| Short Ratio | 1.23 X | 4.00 X |
| Earnings Per Share | (7.64) X | 3.12 X |
| Target Price | 18.0 | |
| Number Of Employees | 57 | 18.84 K |
| Beta | 0.8 | -0.15 |
| Market Capitalization | 41.15 M | 19.03 B |
| Total Asset | 83.94 M | 29.47 B |
| Retained Earnings | (90.06 M) | 9.33 B |
| Working Capital | 48.09 M | 1.48 B |
| Net Asset | 83.94 M |
Note: Acquisition by Samuel Reich of 434000 shares of SAB Biotherapeutics at 5.17 subject to Rule 16b-3 [view details]
SAB Biotherapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as SAB . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 4.13 | |||
| Daily Balance Of Power | (8.50) | |||
| Rate Of Daily Change | 0.96 | |||
| Day Median Price | 4.3 | |||
| Day Typical Price | 4.3 | |||
| Price Action Indicator | (0.1) | |||
| Period Momentum Indicator | (0.17) |
About SAB Biotherapeutics Buy or Sell Advice
When is the right time to buy or sell SAB Biotherapeutics? Buying financial instruments such as SAB Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.| 2021 | 2022 | 2023 | 2024 (projected) | Short and Long Term Debt Total | 6.7M | 5.9M | 5.9M | 5.5M | Total Assets | 79.4M | 50.9M | 83.9M | 63.5M |
Use Investing Ideas to Build Portfolios
In addition to having SAB Biotherapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Gold ETFs Thematic Idea Now
Gold ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Gold ETFs theme has 20 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Gold ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out SAB Biotherapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy SAB Stock please use our How to Invest in SAB Biotherapeutics guide.Note that the SAB Biotherapeutics information on this page should be used as a complementary analysis to other SAB Biotherapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Complementary Tools for SAB Stock analysis
When running SAB Biotherapeutics' price analysis, check to measure SAB Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SAB Biotherapeutics is operating at the current time. Most of SAB Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of SAB Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SAB Biotherapeutics' price. Additionally, you may evaluate how the addition of SAB Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Stocks Directory Find actively traded stocks across global markets | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |
Is SAB Biotherapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of SAB Biotherapeutics. If investors know SAB will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about SAB Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.60) | Earnings Share (7.64) | Revenue Per Share 0.406 | Quarterly Revenue Growth (0.86) | Return On Assets (0.35) |
The market value of SAB Biotherapeutics is measured differently than its book value, which is the value of SAB that is recorded on the company's balance sheet. Investors also form their own opinion of SAB Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is SAB Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because SAB Biotherapeutics' market value can be influenced by many factors that don't directly affect SAB Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between SAB Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if SAB Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, SAB Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.